IsoRay, Inc. Announces Date for Fiscal 2017 Annual Meeting and Shareholder Record Date

Oct 20, 2016

RICHLAND, Wash.Oct. 20, 2016 ­­/PRNewswire/ — IsoRay, Inc. (NYSE MKT: ISR) (the “Company”), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck, and gynecological cancers, today announced that it will hold its fiscal 2017 annual shareholder meeting on Wednesday, December 14, 2016, beginning at 11:00 a.m. (MST), at 8701 East Pinnacle Peak Road, Scottsdale, AZ  85255.  The board of directors has established October 26, 2016 as the record date for determining shareholders entitled to vote at the meeting.

The annual meeting date represents a change of more than 30 days from the anniversary of the Company’s fiscal 2016 annual meeting of shareholders.  As a result, the Company has set a deadline of October 31, 2016 for the receipt of any shareholder proposals for inclusion in the Company’s proxy materials.  Proposals submitted pursuant to Rule 14a-8 of the Securities Exchange Act of 1934, as amended, must comply with the requirements set forth in Rule 14a-8.  Shareholder proposals not submitted pursuant to Rule 14a-8 must comply with the requirements set forth in the Company’s bylaws.  The Company intends to view any proposals received after October 31, 2016 as not having been received within the time periods set forth in Rule 14a-8 or the Company’s bylaws, as applicable.  Any proposal submitted outside this timeframe will not be considered timely and will be excluded from consideration at the annual meeting.

Proposals and notices of proposals should be mailed to: IsoRay, Inc., 350 Hills Street, Suite 106 Richland, WA  99354, Attn: Corporate Secretary.

About IsoRay
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting Join us on Facebook/Isoray. Follow us on Twitter @Isoray.

Logo –

Investor Relations:

Mark Levin

Global IR Group
(501) 255-1910

Media and Public Relations:

Sharon Schultz
Schultz Public Relations
(302) 539-3747